Teva Pharmaceutical (NYSE:TEVA) Stock Upgrade
In a comprehensive report made public on Friday, 4 December, expert analysts at the Guggenheim division of equities upgraded shares of Teva Pharmaceutical (NYSE:TEVA) stock from a “Neutral” to a respectable “Buy” rating.
From a total of 21 analysts covering Teva Pharma (NYSE:TEVA) stock, 16 rate it a ”Buy”, 0 a “Sell”, and 8 a ”Hold”. This means that 67% of the ratings are positive. The highest target price is $100 while the lowest target price is $62. The mean of all analyst targets is $76.43 with a 25.74% above today’s ($63.55) stock price. Teva Pharma was the topic of 14 analyst reports since July 21, 2015 according to the firm StockzIntelligence Inc. Goldman Sachs upgraded shares on November 23 to “Buy” rating. Goldman Sachs maintained shares with “Buy” rating and $80 target share price in a report from an August 10. Nomura initiated TEVA stock in a recent report from September 29 with “Neutral” rating. RBC Capital Markets maintained the rating on July 29. RBC Capital Markets has a “Outperform” rating and a $85 price target on shares. Finally, Morgan Stanley reinitiated the stock with “Overweight” rating in a report issued on a July 29.
The stock increased 0.03% or $0.02 during the last trading session, striking $63.55. Approximately 8,585 shares of stock traded hands. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) has risen 2.19% since May 1, 2015 and is uptrending. It has outperformed by 4.97% the S&P500.
Teva Pharmaceutical Industries Limited is a global pharmaceutical and drug company. The company has a market cap of $61.24 billion. The Company’s generic products cover almost every major therapeutic area. It has 30.79 P/E ratio. The Firm operates its business in two divisions: Generic medicines, which makes and sells generic pharmaceutical products in several dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams, and Specialty medicines, which delivers solutions to patients and providers via medicines, devices and services.
According to Zacks Investment Research, “TEVA Pharmaceuticals USA, the business is to develop, manufacture, and market generic pharmaceuticals. Teva USA sells its products to chains, wholesalers, distributors, hospitals, managed care entities, and government agencies. The company markets a variety of dosage forms, including both extended and immediate release tablets and capsules, creams, ointments, solutions, and suspensions. Key therapeutic areas are the analgesic, anti-infective, cardiovascular, CNS, dermatological and anti-inflammatory categories.” Get a free copy of the Zacks research report on Teva Pharmaceutical Industries Ltd (ADR) (TEVA).